沃爾格林就Theranos的血液測試消費者索賠達成和解
格隆匯5月24日丨據市場消息,沃爾格林(WBA.US)已經與亞利桑那州和加利福尼亞州的消費者達成了初步和解,這些消費者在該連鎖藥店購買了Theranos的血液測試。這些消費者聲稱,沃爾格林對該公司正在進行的欺詐行為 "故意視而不見"。此前,Theranos公司的產品,甚至曾經成功打入連鎖藥店沃爾格林,在全美開疆擴土,聲稱為無數消費者提供所謂的便捷式血液檢測服務。Theranos公司吹噓其血液測試只需少量的血液就能發揮作用。由創始人兼首席執行官伊麗莎白-霍姆斯(Elizabeth Holmes)推廣的這項技術並沒有發揮作用。霍姆斯去年被認定犯有欺詐罪,並將於5月30日入獄服刑,刑期為11年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.